Quantumzyme Corp. Outlines 2026 Strategic Priorities Following 2025 Research Progress

Quantumzyme Corp., a biotransformation company focused on sustainable pharmaceutical manufacturing, provided an overview of corporate developments during 2025 and outlined its operational priorities and strategic objectives for 2026. The company also confirmed plans for a pending corporate name change and corresponding trading symbol change, subject to applicable regulatory approvals. During 2025, Quantumzyme continued to advance its operations as an early-stage biotechnology company focused on enzyme research and development for potential applications in sustainable chemistry. Key activities during the year included regulatory and reporting status development, research and development progress in enzyme engineering and biocatalytic process development, intellectual property activity with patent applications, and corporate communications updates.

Throughout 2025, the company remained focused on foundational research, capital discipline, and regulatory compliance while navigating the challenges typical of early-stage biotechnology development. During 2025, Quantumzyme began expanding its internal focus on the use of artificial intelligence and computational methods to support its enzyme research and development activities. The company evaluated data-driven approaches, including machine learning techniques and computational modeling, as tools to assist in enzyme discovery, structure-function analysis, and research prioritization. These artificial intelligence initiatives are intended to complement the company's existing laboratory research by improving the efficiency of experimental design and data analysis. Quantumzyme's use of AI-related tools remains at a research and evaluation stage and is focused on internal decision support rather than commercial software development.

In late 2025, Quantumzyme's Board of Directors approved a proposal to change the company's legal name to Quantum Genesis AI Corp. and to seek a corresponding change to its trading symbol. The proposed name reflects the company's intention to place greater emphasis on computational and data-driven approaches within its enzyme research activities. The company has submitted the required documentation in connection with this proposed corporate action. The name and symbol change remain subject to FINRA approval and the completion of all applicable regulatory and corporate action requirements. There can be no assurance regarding the timing or approval of these changes, though the corporate name change and symbol change are expected to be completed during the first quarter of 2026.

Looking ahead to 2026, Quantumzyme expects to focus on several key priorities. These include continued research and evaluation of enzyme candidates and biocatalytic pathways through internal testing, optimization, and feasibility assessment while maintaining a research-stage development posture. The company plans to continue refining computational modeling and data-driven research tools, including artificial intelligence techniques, to support enzyme research and improve internal research efficiency. Quantumzyme will evaluate potential collaboration, licensing, or development opportunities with third parties, including pharmaceutical and chemical industry participants. The company intends to increase visibility through appropriate scientific forums, industry events, and investor communications, consistent with regulatory requirements. Additionally, Quantumzyme will assess longer-term corporate objectives, including reporting status, market structure considerations, and capital planning, as appropriate. The company cautions that its objectives for 2026 are subject to various risks and uncertainties, including technical challenges, capital availability, regulatory considerations, and market conditions. For more information, please visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.